56200 Federal Register / Vol. 62, No. 209 / Wednesday, October 29, 1997 / Notices

constituency. Input from the meeting

participants will be used to complete a

situation analysis (Phase I) in a threephase process to develop a national

outreach/marketing strategy to increase

public participation in recreational

fishing and boating.

Dated: October 17, 1997.

Jamie Rappaport Clark,

Director.

[FR Doc. 97–28628 Filed 10–28–97; 8:45 am]

BILLING CODE 4310–55–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances;

Notice of Registration

By Notice dated July 21, 1997, and

published in the Federal Register on

August 26, 1997, (62 FR 45271),

Applied Science Labs, Inc., A Division

of Altech Associates, Inc., 2701

Carolean Industrial Drive, P.O. Box 440,

State College, Pennsylvania 16801,

made application by renewal to the

Drug Enforcement Administration to be

registered as an importer of the basic

classes of controlled substances listed

below:

Drug Schedule

Heroin (9200) ................................ I

Morphine (9300) ........................... II

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Applied Science Labs to

import listed controlled substances is

consistent with the public interest and

with United States obligations under

international treaties, conventions, or

protocols in effect on May 1, 1971, at

this time. Therefore, pursuant to Section

1008(a) of the Controlled Substances

Import and Export Act and in

accordance with Title 21, Code of

Federal Regulations, Section 1301.34,

the above firm is granted registration as

an importer of the basic classes of

controlled substances listed above.

Dated: October 17, 1997.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–28558 Filed 10–28–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA #171I]

Controlled Substances: 1997

Aggregate Production Quota

AGENCY: Drug Enforcement

Administration (DEA), Justice.

ACTION: Interim notice establishing a

1997 aggregate production quota and

request for comments.

SUMMARY: This interim notice

establishes a revised 1997 aggregate

production quota for codeine (for sale),

a Schedule II controlled substance, as

required under the Controlled

Substances Act of 1970.

DATES: This is effective on October 29,

1997. Comments must be received on or

before November 28, 1997.

ADDRESSES: Send comments or

objections to the Acting Deputy

Administrator, Drug Enforcement

Administration, Washington, D.C.

20537, Attn.: DEA Federal Register

Representative/CCR.

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and

Chemical Evaluation Section, Drug

Enforcement Administration,

Washington, D.C. 20537, (202) 307–

7183.

SUPPLEMENTARY INFORMATION: Section

306 of the Controlled Substances Act

(21 U.S.C. 826), requires the Attorney

General to establish aggregate

production quotas for controlled

substances in Schedules I and II each

year. This responsibility has been

delegated to the Administrator of the

DEA pursuant to Section 0.100 of Title

28 of the Code of Federal Regulations.

The Administrator, in turn, has

redelegated this function to the Acting

Deputy Administrator of the DEA

pursuant to Section 0.014 of Title 28 of

the Code of Federal Regulations.

The DEA established revised 1997

aggregate production quotas for

controlled substances in Schedules I

and II, including codeine (for sale), in a

Federal Register notice published on

August 15, 1997 (62 FR 43750). Since

publication of the revised 1997

aggregate production quotas, DEA has

received information which necessitates

an immediate increase in the revised

1997 aggregate production quota for

codeine (for sale). The increase for

codeine (for sale) is necessary to meet

additional and unforeseen domestic

manufacturing needs and export

requirements. For these reasons, an

interim notice is being published.

Therefore, under the authority vested

in the Attorney General by Section 306

of the Controlled Substances Act of

1970 (21 U.S.C. 826), delegated to the

Administrator of the DEA by Section

0.100 of Title 28 of the Code of Federal

Regulations, and redelegated to the

Acting Deputy Administrator, pursuant

to Section 0.104 of Title 28 of the Code

of Federal Regulations, the Acting

Deputy Administrator hereby orders

that the revised aggregate production

quota for the following controlled

substance, expressed in grams of

anhydrous base, be established as

follows:

Basic class

Established

revised

1997 quota

Codeine (for sale) ................. 58,140,000

All interested persons are invited to

submit their comments in writing

regarding this interim notice.

The Office of Management and Budget

has determined that notices of aggregate

production quotas are not subject to

centralized review under Executive

Order 12866. This action has been

analyzed in accordance with the

principles and criteria contained in

Executive Order 12612, and it has been

determined that this matter does not

have sufficient federalism implications

to warrant the preparation of a

Federalism Assessment.

The Acting Deputy Administrator

hereby certifies that this action will

have no significant impact upon small

entities whose interests must be

considered under the Regulatory

Flexibility Act, 5 U.S.C. 601 et seq. The

establishment of annual aggregate

production quotas for Schedule I and II

controlled substances is mandated by

law and by international treaty

obligations. Aggregate production

quotas apply to approximately 200 DEA

registered bulk and dosage from

manufacturers of Schedule I and II

controlled substances. The quotas are

necessary to provide for the estimated

medical, scientific, research and

industrial needs of the United States, for

export requirements and the

establishment and maintenance of

reserve stocks. While aggregate

production quotas are of primary

importance to large manufacturers, their

impact upon small entities is neither

negative nor beneficial. Accordingly, the

Acting Deputy Administrator has

determined that this action does not

require a regulatory flexibility analysis.

Dated: October 22, 1997.

James S. Milford,

Acting Deputy Administrator.

[FR Doc. 97–28557 Filed 10–28–97; 8:45 am]

BILLING CODE 4410–09–M